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Abstract
Introduction: With the aging US population, chronic liver diseases are becoming more commonly diagnosed in the geriatric 
population. Advanced age leads to changes in liver blood flow, volume, morphology and normal physiology. This predisposes 
elderly patients to develop certain chronic liver diseases. Also, the clinical course and management differ in an older patient 
when compared to a younger patient. Some causes of chronic liver disease in the geriatric population include Hepatitis A, B, C, 
Non-Alcoholic Fatty liver disease, prolonged alcohol use and inflammation. Many chronic liver diseases are characterized by a 
slow, indolent course of progression with non-specific symptoms and thus may lead to diagnosis at a later age. The presence of 
an advanced liver disease, cirrhosis, and hepatocellular carcinoma are becoming more frequent in older patients and often the 
first clinical presentation.
Aim: The aim of this study is to highlight hepatic diseases in the geriatric population to better understand the scope of the clini-
cal management including liver transplantation.
Method: PubMed, MEDLINE, EMBASE, and EMBASE classic were searched to research published articles, case reports, 
cross-sectional and case-control studies reporting regarding aging and the liver diseases.
Result: Decreases in the functioning of the liver and other organs, as well as, alterations in immune functions should be taken 
into consideration in the management of the liver diseases. Aging has been shown to not only enhance vulnerability to acute liver 
injury but also increase the susceptibility of the fibrotic response. Aging has a significant impact on the risk and poor prognosis 
of various liver diseases including NAFLD, ALD, HCV, and liver transplantation. The diagnosis of advanced liver disease is 
important to make in the elderly population since many of the condition’s features are treatable and can lead to improved qual-
ity of life and, most importantly, decrease the likelihood of acute care hospitalization, which carries a high risk of nosocomial 
infections and therapeutic mishaps in the aged population.
Conclusion: Geriatric patients show various changes in the liver, which play a role in the clinical characteristics of liver diseases 
in these patients. Geriatric patients with risk factors for hepatitis should be screened for liver disease, along with those that have 
a family history of liver diseases, or a history of long-term or heavy alcohol consumption. Age cannot be a single exclusion crite-
rion from the liver transplantation, and an individualization strategy, which takes into consideration all risk factors of a recipient, 
needs to be considered. We suggest geriatric patients should be a candidate for liver transplant, and the healthcare team treating 
our elderly generation to collaborate for these patients for them to have a smoother transition both in pre-transplant phase and 
post-transplant phase.
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Introduction
Aging causes time-dependent, inevitable physiologic organ 
dysfunction that alters normal homeostasis and is a major risk 
factor for cancer development [1]. In the United States, as of 2009, 
there are 39.6 million people older than the age of 65, equating to 
13% of the country’s total population. This number is expected 
to increase to 72 million or 19% of the total US population by 
2030 [2-4]. Aging has shown increase vulnerability to acute liver 
injury as well as progression to liver fibrosis. This is associated 
with associated with poor prognosis of various liver diseases 
including Nonalcoholic Fatty Liver Disease (NAFLD), Alcoholic 
Liver Disease (ALD), Hepatitis C (HCV), Hepatocellular 
Carcinoma (HCC) and Liver Transplantation (LT). Studies have 
compared changes in the liver due to liver diseases with the 
process of aging [5]. Approximately, 8 million Americans suffer 
from chronic hepatic diseases, of which, more than half a million 
people have cirrhosis and nearly, 31 thousand Americans die 
each year from cirrhosis [6-8]. Old age seems to favor NAFLD, 
NASH, and ultimately HCC, in agreement with the inflammatory 
aging theory, according to which aging accrues inflammation [5]. 
The higher vulnerability to environmental factors (Especially 
oxidative stress), the reduction in the rate of hepatic blood flow, 
the reduced mitochondrial capacity and the impaired immunity are 
all mechanisms possibly involved in a faster progression of liver 
damage [9].
Aging and Liver Volume, Blood Flow, And Function
Both liver volume and blood flow decrease significantly 
with age. Hepatic blood flow is estimated to be decreased by 
35%-50% in the elderly and may be responsible for age-related 
reductions in liver volume [10]. The neural fat and cholesterol 
volumes in the liver gradually expand as one gets older, and 
therefore causes an increase in total serum cholesterol and high-
density lipoprotein cholesterol. Meanwhile, the metabolism of the 
low-density lipoprotein cholesterol decreases by 35%. The serum 
γ-glutamyltransferase and alkaline phosphatase levels increase 
with aging, while Alanine Aminotransferase (ALT) concentrations 
and serum bilirubin are gradually reduced with age, independent of 
components of the metabolic syndrome, the serum aminotransferase 
maintains normal level and albumin remains within normal limits 
or is slightly decreased due to aging [11]. Humans show a slight 
decrease in the serum albumin concentration or maintain the 
normal level in the natural aging process [11].
Alanine Aminotransferase (ALT) concentrations have been 
reported to decrease with age, independent of components of the 
metabolic syndrome. These findings suggest the need to identify 
an optimal cut-off point for normal ALT in Geriatric patients [12]. 
Hepatic Encephalopathy (HE) also can occur because of portal 
hypertension. Resistance to blood flow leads to shunting of blood 
around the liver, allowing blood from the gut containing ammonia 
and other byproducts of bacterial metabolism to bypass the liver 
and reach the systemic circulation [7]. Exposing the brain to these 
chemicals can result interfere with the normal synaptic transmission 
of electrical and chemical signaling. As a result, cognition and 
memory are affected, leading to memory loss, impaired thinking, 
and an inability to perform fine motor tasks [13,14].
Aging-Related Changes in Liver Cells
Aging-related changes in liver cells include volume changes, 
polyploidy, accumulation of dense bodies (Lipofuscin) inside liver 
cells, a decreased area of the smooth endoplasmic reticulum, and a 
declining number and dysfunction of mitochondria [15]. Compared 
with the studies on liver cells, relatively little is known about what 
kind of effect aging has on liver sinusoidal endothelial cells, Kupffer 
cells, and hepatic stellate cells [16]. The functionality of Kupffer 
cells is to remove antigen–antibody complexes or nanoparticles 
such as senescent cell fragments in the liver sinusoidal vascular 
system and is important to point out that aging increases the number 
and activation level of Kupffer cells [17]. A study by Sotaniemi, et 
al [18], suggested that drug metabolism is reduced by up to 30% 
after 70 years of age, and that a reduction in liver cytochrome P450 
may also contribute to decreased drug metabolism. Cytochrome 
P450 activity was shown to be 32% lower in subjects > 70 years 
than in subjects aged 20-29 years [18].
First-pass hepatic uptake (Phase I) of drugs has been 
reported to be decreased in the elderly, possibly due to reduced 
liver volume and hepatic blood flow, leading to a decline in 
hepatic drug metabolism [19]. Metabolism of drugs with low 
phase I hepatic metabolism is likely to be impaired mainly by 
liver volume reduction [19]. Volume and blood flow changes 
coupled with decreased cytochrome P450 activity can affect drug 
metabolism, increasing susceptibility to drug-induced liver injury 
[20]. Immune responses against pathogens or neoplastic cells 
are decreased in the elderly, although individuals may also be 
predisposed to autoimmunity through impairment of dendritic cell 
maturation and reduction of regulatory T cells [21]. Such changes 
in immune functions could alter the pathogenesis of viral hepatitis 
and autoimmune liver diseases and development of hepatocellular 
carcinoma [22,23]. Geriatric patients have significantly decreased 
reserve functions of various other organs as well, reducing their 
tolerability to treatments for liver diseases [24].
Hepatic Diseases of Elderly
NAFLD
Non-alcoholic fatty liver disease is a clinical syndrome 
predicted to be the next global epidemic affecting millions of 
people worldwide, especially the geriatric population [25,26]. The 
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natural course of this disease including its subtype, Non-Alcoholic 
Steatohepatitis (NASH), is not clearly defined especially in the 
elderly segment of the US population [26]. NAFLD affects mainly 
the middle-aged and the elderly and previously was reported be 
benign, however more recent studies suggest an increased mortality 
in the patients older than 60-year [27]. With advancing age come 
more risk factors for its development. Aging increases risk factors 
which predispose progression to NAFLD. Older patients have 
more severe biochemical, hematological, and histological changes 
[28]. The pivotal role of inflammation in the pathogenesis of liver 
steatosis has been emphasized in the literature; the link between 
insulin resistance and inflammation and the possible role of 
C‐Jun N‐Terminal Kinases (JNKs) in the progression of this 
condition has been clearly defined, along with the involvement of 
endoplasmic reticulum stress and of the unfolded protein response 
[29]. Aging-related alterations of the pro-inflammatory vs anti-
inflammatory balance, described as the inflammatory aging theory 
may represent the biological background of these findings [30]. 
Current guidelines for treatments for NAFLD are to control body 
weight and treatment of metabolic disorders by changing lifestyle 
and improve insulin resistance [31,32].
Metformin and thiazolidinedione’s are insulin sensitizers, 
which metformin is known to be effective in reducing body weight 
and improving insulin resistance [33], but its histological effect of 
improving necrotic inflammation in the NASH has not been proven 
[34,35]. In very rare cases, it can cause lactic acidosis in the elderly 
[36,37]. Another treatment option would be bariatric surgery, but 
is important to note that bariatric surgery causes an upsurge in the 
morbidity rate among geriatric patients compared with younger 
patients, and is no significant difference in the mortality rate except 
for those with patients with cardiovascular diseases [38,39]. Liver 
transplantation can be an option for patients with decompensated 
liver cirrhosis due to NASH and, it is also worthy to not that, 
in the geriatric patients, careful consideration should be paid in 
consideration of common age-related comorbidities, which has a 
significant influence on their survival and hospitalization period 
after liver transplantation, due to cardiovascular complications 
which they will have [40,41]. More accurate understanding of 
the molecular pathways, gut microbiome analysis, and precise 
investigation of the mechanisms of geriatric NAFLD will help 
in identifying the most appropriate diagnostic and therapeutic 
approach for individual geriatric patients [42-46]. With aging, 
the liver undergoes substantial changes in structure and function 
that are associated with significant impairment of detoxification 
activities and many hepatic metabolic dysfunctions [47-49].
Acute Liver Failure
Acute Liver Failure (ALF), is an uncommon condition with 
potentially devastating consequences, including an increased rate 
of short-term morbidity and mortality [50-52]. Common causes 
for ALF in elderly is excessive alcohol consumption and in some 
rare cases which physicians should pay close attention for is overly 
excessive use of acetaminophen [53,54]. The primary treatment 
for alcoholic liver disease is abstinence from drinking and provide 
sufficient nutrients and vitamins, but in geriatric patients, this is a 
major problem due to prolonged use of alcohol and late diagnosis 
of ALF [55]. Half of the elderly patients who develop cirrhosis die 
within 1 year of diagnosis [56]. Glucocorticoid treatment can be 
helpful for some patients with mild to moderate alcohol hepatitis 
whose Maddrey’s discriminant function scores are higher than 32 
[57]. However current research has described glucocorticoids-
induced hyperglycemia elderly patients and physicians should 
be aware of this complication [58]. For patients who have a 
contraindication for steroids, pentoxifylline, a TNF-α Inhibitor 
(TNFI), can be considered as an alternative treatment which the 
retention rate of TNFI in the elderly is comparable with that in 
younger patients [59]. It is imperative to identify geriatric patients 
with ALF as soon as possible to transfer them to a liver transplant 
center for an evaluation and life style modification. Emergent liver 
transplant in the geriatric patient with ALF may place the patient at 
risk for severe complications in the postoperative period [60], but 
in the long run, may help to prevent mortality.
Hepatitis A
Although Acute Hepatitis A (HAV) infection is usually self-
limiting in general population. However, elderly patients with 
acute HAV infection can experience hepatocellular dysfunction 
with frequent jaundice and coagulopathy, as well as an increased 
incidence of complications, such as prolonged pancreatitis, 
cholestasis, and ascites [61]. During 1994 and 1995, Memphis 
and Shelby County, Tennessee, experienced an epidemic of 
HAV, which 42% of patients aged 70 years or older required 
hospitalization compared with 3%-20% of adults aged 40-49 years 
[62]. Vaccination for HAV should be offered for those who plan 
to travel to endemic areas, especially patients living in nursing 
homes.
Hepatitis B
Acute Hepatitis B Virus (HBV) infection is very uncommon 
in the geriatric patients because the opportunities for acquiring 
HBV infection are estimated to be low in this population. However, 
HBV infections have been reported in residents of nursing homes 
[63]. The rate of progression to chronic hepatitis B is higher in 
the elderly vs younger patients [64]. A report of an outbreak in 
a nursing home showed that 59% of patients older than 65 years 
of age developed chronic HBV infection [64]. Regarding the lab 
results of elderly patients with HBV infection, older age and male, 
in addition to serum HBV DNA levels, are regarded as risk factors 
not only for progression to cirrhosis [65], but the development 
of HCC [66]. Nucleoside analogs are effective in treating HBV 
infected patients, with similar efficacy in the elderly as in younger 
patients [67]. Interferon-based therapy may also be effective for 
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the treatment of chronic HBV infection, however, its therapeutic 
effects are inferior in elderly patients [68]. Vaccinations should be 
considered if patients have not been vaccinated.
Hepatitis C
The population infected with HCV is aging as most in the US 
acquired the infection during World War II [69]. A total of 320,000 
deaths, 157,000 cases of HCC, and 203,000 cases of cirrhosis 
are predicted in the US for the upcoming 35 years, despite the 
highly effective and readily available treatment regimens [70]. An 
increased number of Americans with advanced liver diseases in part 
can be attributed to the 3.3% prevalence of HCV in the geriatric 
population [71]. According to a research by Poynard, et al. [9], age 
itself is more important than duration of infection for predicting 
the occurrence of cirrhosis. This will create a tremendous burden 
on the healthcare system, including skilled nursing and long-
term care facilities [72-75]. In the US, most patients with HCV 
infection were born between 1945 and 1965, who acquired the 
infection during the 1970s and 1980s from exposure to blood or 
blood products [76-78]. Evidence shows that treatment of HCV 
can prevent the progression of end-stage liver disease in geriatric 
patients [79]. Since the first introduction of the interferon-alone 
treatment, the antiviral treatments for chronic hepatitis C have 
developed dramatically through the combination therapy of peg-
interferon-α and ribavirin to direct-acting antiviral agents such as 
protease inhibitors and polymerase inhibitors.
When the elderly people aged more than 65 years are treated 
with a combination therapy of peg-interferon-α and ribavirin, their 
Sustained Virological Response (SVR) is lower than those under 
65 years old (Genotype 1: 22.9 vs. 47.3%; genotype 2: 65.6 vs. 
82.9%), whereas their treatment termination rate is higher due 
to side-effects (genotype 1: 42.9 vs. 24.1%; genotype 2: 24.4 vs. 
10.8%) [80-82]. The combination of three agents such as peg-
interferon-α., telaprevir, and ribavirin is given to genotype 1 patients 
showed no significant difference in their SVR between the young 
and elderly [83]. Also, this treatment regime was discontinued 
due to complications such as severe malaise [84-86]. According 
to a research by Pawlotsky [87], it is important to state that, all-
oral, interferon-free combinations of drugs are expected to cure 
more than 90% of infections, but this has not been tested in elderly 
patients [87]. Current research supports that the supplementation 
of vitamin D and vitamin B12 increases the SVR, and as elderly 
people have a lack of these vitamins, they should be taking these 
supplements [88-92].
SVR has been shown to improve biochemical characteristics 
and portal hypertension in some patients diagnosed with HCV, it 
is unclear in which specific patients may benefit from treatment 
with a history of decompensated liver disease [93]. It is thoroughly 
documented that HCV infection has a negative impact on the 
quality of life of elderly patients, until this date, the complexity of 
treatment and the lack of supportive data in elderly patients have 
significantly limited the treatment options [84]. Now that the era 
of baby boomers and populations is rapidly changing, and that 
new IFN-free treatment options are becoming widely available, 
the limited but available evidence concerning the benefit of viral 
eradication in the elderly population should be carefully considered 
[69]. The faster the health care system changes their policy with 
respect to an a priori obstacle for anti-HCV treatment in the elderly, 
the sooner we will begin to help many geriatric patients diagnosed 
with HCV [69]. HCV infection is the most common indication for 
Orthotopic Liver Transplantation (OLT) in the United States [94]. 
Recent studies from selected centers have suggested that older 
donor age is associated with worse outcomes after transplantation 
for HCV [95].
According to a research by Dultz, et al. [96] both older donor 
age and older recipient age plus markers of severity of disease, 
including requirement for mechanical ventilation and renal 
insufficiency, are negatively associated with survival after liver 
transplantation [94]. According to a research by Pyrsopoulos, et 
al. [97] the combination of LED/SOF with RBV for 12 weeks or 
ledipasvir/sofosbuvir for 24 weeks is very effective and safe in 
treating OLT recipients with recurrent HCV [97]. These factors 
should be considered when assessing OLT recipient and donor 
candidacy in patients with HCV. Concerted efforts are necessary 
to increase diagnosis and treatment rates, optimize care of patients 
with cirrhosis and HCC and provide care to liver transplant 
recipients to reduce the overall HCV-related disease burden in the 
United States [96].
Cholestatic Liver Disease
Primary Sclerosing Cholangitis (PSC) and Primary Biliary 
Cirrhosis (PBC) are chronic diseases which can manifest in adult 
patients [98]. In a recent study by Tanaka, et al. [98] they reported 
that conclude that PSC in the young resembles those in Europe and 
the USA in terms of the onset age and prevalence of IBD, while PSC 
in the elderly is really unique in Japan. Presenting complications of 
elderly patients with PSC is no different than those of the younger 
patients [99], but there is certain degree of cholangiocarcinoma 
presentation in older patients [100-102]. Eventually all patients 
with PSC will require LT, and is better for the elderly patient to 
receive the LT before the age of 60 [99]. According to a research 
by Newton, et al. [103] they reported that 35% of patients out of 
1000 examined had PBC. Symptoms of clinical presentation was 
no different for young patients versus the elderly [103]. Although 
there has been reported that a 92 year-old men with PBC after 
under undergoing Computed Tomography (CT) and ultrasound 
scans of his abdomen revealed a large hepatic tumor, which 
was confirmed on liver biopsy to be HCC [104]. Furthermore, 
biomarkers reflecting disease activity and prognosis in Primary 
Sclerosing Cholangitis (PSC) have not been firmly established and 
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due to complex interplay which exists between IBD, PSC, and LT 
which requires explanation with further research.
Hepatocellular Carcinoma
With age the risk of HCC increases significantly, and this 
is independent of prolonged HCV infection as a shorter interval 
between acquiring HCV infection and the diagnosis of HCC has 
been demonstrated in elderly patients [105]. Many elderly HCC 
patients with intermediate to terminal stage at their initial diagnosis 
will have more compromised liver regeneration and comorbidities 
compared with those of younger age [106]. Elderly patients require 
long-term follow-up even after viral eradication and especially 
male patients with liver cirrhosis since research has shown that 
they are prone to developing HCC [107]. Hepatic resection for 
HCC can be performed safely and effectively in elderly patients 
[108-110]. A recent report by Borzio, et al. [111] showed that age 
did not predict short-mid-term survival within 24 months, while 
it was a significant independent predictor of long-term survival. 
Also age had a substantial long-term survival effect mainly on 
early HCC stages (Barcelona Clinic for Liver Cancer [BCLC] 
0-A), its influence on BCLC B stage was shown to be lower, while 
it was negligible for advanced terminal stages Age should not 
impact on short-mid-term prognosis of elderly patients with HCC 
and should not represent a restriction to the management [112]. 
The pool of elderly patients with the history of HCC receiving a 
liver transplantation is increasing [113]. This can be attributed to 
the improvement of HCC surveillance approaches and diagnostic 
techniques leading to earlier diagnoses of HCC in the elderly 
population.
Geriatric Liver Transplant
Liver Transplant (LT) is a standard treatment for End-
Stage Liver Disease (ESLD). At present, 1-year survival rate is 
approximately 90% and 10-year survival rate may exceed 70% 
in many indications [114,115]. Patients with ESLD will require 
liver transplantation to prevent morbidity and mortality associated 
with end-stage-liver disease [116]. The proportion of adult liver 
transplantation recipients in the United States older than 60 years 
of age increased from 10% in 1990 to more than 20% by 1999 
[117]. The era when an ideal liver donor was younger than the 
age of 40 years seems to have be gone out of current practice 
management [118]. Many transplant programs have expanded 
eligibility to include patients previously ineligible because of 
advanced age [119]. Several studies showed that outcomes after 
LT with livers of patients older than 70-years are comparable, and 
sometimes even better compared to younger donors, with 1-year 
and 3-year patient and graft survival ranging 66-95% and 58-91%, 
respectively [120].
According to a research by Adani, et al. [121], clinical 
outcomes after liver transplantation in the elderly are nearly 
similar to young people, considering if individual surgery risks 
are equivalent [121]. United Network for Organ Sharing Database 
conducted a study which revealed prognostic factors: they found 
that diabetes mellitus, the ventilator status, history of HCV, 
creatinine at least 1.6 mg/dl, and combined donor age and the 
recipient age are the most prevailing prognostic indicators among 
the recipients of LT older than 60-years old [122]. If the numbers 
of positive indicators among them are 0, 1, and 2, their 5-year 
survival rates are recorded at 75, 69, and 58%, respectively. If 
the number of positive indicators is more than three, the elderly 
patients 5-year survival rate was below 50% [123].
Although it is important to note that geriatric patients may 
have multiple risk factors, including artery disease or malignancy, 
coronary disease and face age-related quality of life impairments, 
such as incontinence, gate instability, immobility, dementia, and 
many are on regimen of polypharmacy [124]. It is important 
for the healthcare team to also take in account these parameters 
when considering the patient for LT. A successful LT depends 
on the liver’s structure and hepatic function, but as research 
indicate these parameters decline with the process of aging 
[125]. Considering that there is a rise in elderly patients the aging 
population is increasingly suffering from cerebrovascular disease 
[126-131], the use of chronologically old, but biologically young 
liver donors would expand the donor pool and, hopefully, reduce 
waitlist mortality. Advanced age alone should not be considered 
a contraindication for LT due to potentially poor quality of life 
outcomes [132]. Further research is necessary to confirm whether 
and which geriatric-like measures can be used to select livers of 
older donors for LT.
Conclusion
Geriatric patients show various changes in the liver, which 
play a role in the clinical characteristics of liver diseases in these 
patients. Decreases in the functioning of the liver and other organs, 
as well as, alterations in immune functions should be taken into 
consideration in the management of the liver diseases. Aging 
has been shown to not only enhance vulnerability to acute liver 
injury but also increase the susceptibility of the fibrotic response. 
Aging has a significant impact on the risk and poor prognosis 
of various liver diseases including NAFLD, ALD, HCV, and 
liver transplantation. The diagnosis of advanced liver disease is 
important to make in the elderly population since many of the 
condition’s features are treatable and can lead to improved quality 
of life and, most importantly, decrease the likelihood of acute care 
hospitalization, which carries a high risk of nosocomial infections 
and therapeutic mishaps in the aged population. Geriatric patients 
with risk factors for hepatitis should be screened for liver disease, 
along with those that have a family history of liver diseases, or a 
history of long-term or heavy alcohol consumption. Age cannot 
be a single exclusion criterion from the liver transplantation, and 
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an individualization strategy, which takes into consideration all 
risk factors of a recipient, needs to be considered. We suggest 
geriatric patients should be a candidate for liver transplant, and the 
healthcare team treating our elderly generation to collaborate for 
these patients for them to have a smoother transition both in pre-
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